FDA advisory vote on Grail's cancer blood test could reshape regulatory path

Grail's shares surged after FDA released briefing documents ahead of an advisory committee meeting on its multi-cancer detection test. The vote will signal regulatory stance on liquid biopsy tests, impacting Grail's commercial prospects and the broader diagnostics sector. Outcome uncertain, with potential to set precedent for FDA oversight of such tests.